About: Prednisolone for the first rhinovirus‐induced wheezing and 4‐year asthma risk: A randomized trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prednisolone for the first rhinovirus‐induced wheezing and 4‐year asthma risk: A randomized trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Prednisolone for the first rhinovirus‐induced wheezing and 4‐year asthma risk: A randomized trial
Creator	Vuorinen, Tytti Turunen, Riitta Gern, James Vahlberg, Tero Lukkarinen, Minna Camargo, Carlos Koistinen, Annamari Ruuskanen, \| Säätiö, Sigrid Tuomas, \| Tutkimussäätiö, Hengityssairauksien
source	Medline; PMC
abstract	BACKGROUND: Previous findings show that corticosteroid treatment during the first acute wheezing episode may reduce recurrent wheezing in children with high rhinovirus genome load at 12‐month follow‐up. Longer‐term effects have not been investigated prospectively. METHODS: After PCR confirmation of rhinovirus from nasopharyngeal aspirate, 79 children with the first acute wheezing episode were randomized to receive orally prednisolone or placebo for 3 days. The initiation of asthma control medication before the age of 5 years was confirmed from medical record and/or from parental interview. The outcome was the time to initiation of regular asthma control medication. Interaction analysis examined rhinovirus genome load. RESULTS: Fifty‐nine (75%) children completed the follow‐up. Asthma control medication was initiated in 40 (68%) children at the median age of 20 months. Overall, prednisolone did not affect the time to initiation of asthma control medication when compared to placebo (P=.99). Rhinovirus load modified the effect of prednisolone regarding the time to initiation of asthma control medication (P‐value for interaction=.04). In children with high rhinovirus load (>7000 copies/mL; n=23), the risk for initiation of medication was lower in the prednisolone group compared to the placebo group (P=.05). In the placebo group, asthma medication was initiated to all children with high rhinovirus load (n=9) during the 14 months after the first wheezing episode. CONCLUSIONS: Overall, prednisolone did not affect the time to initiation of asthma control medication when compared to placebo. However, prednisolone may be beneficial in first‐time wheezing children whose episode was severe and associated with high rhinovirus load. (ClinicalTrials.gov, NCT00731575).
has issue date	2017-08-06(xsd:dateTime)
bibo:doi	10.1111/pai.12749
bibo:pmid	28660720
has license	no-cc
sha1sum (hex)	b91cd45e5add5a4ab9e8971919e32e1a28bcbbe6
schema:url	https://doi.org/10.1111/pai.12749
resource representing a document's title	Prednisolone for the first rhinovirus‐induced wheezing and 4‐year asthma risk: A randomized trial
has PubMed Central identifier	PMC7168117
has PubMed identifier	28660720
schema:publication	Pediatr Allergy Immunol
resource representing a document's body	covid:b91cd45e5add5a4ab9e8971919e32e1a28bcbbe6#body_text
is schema:about of	named entity 'wheezing' named entity 'wheezing' named entity 'follow-up' named entity 'rhinovirus' named entity 'wheezing' named entity 'wheezing' named entity 'rhinovirus' named entity 'immunoglobulin' named entity 'asthma' named entity 'rhinovirus' named entity 'asthma' named entity 'neutrophils' named entity 'prednisolone' named entity 'wheezing' named entity 'nasopharyngeal aspirate' named entity 'genome' named entity 'rhinovirus' named entity 'genome' named entity 'inflammatory' named entity 'genome' named entity 'rhinovirus' named entity 'enteroviruses' named entity 'asthma' named entity 'risk factor' named entity 'genome' named entity 'rhinovirus' named entity 'rhinovirus' named entity 'rhinovirus' named entity 'secondary prevention' named entity 'IBM' named entity 'asthma' named entity 'asthma' named entity 'prednisolone' named entity 'prednisolone' named entity 'genome' named entity 'rhinovirus' named entity 'genome' named entity 'genome' named entity 'rhinovirus' named entity 'prednisolone' named entity 'placebo group' named entity 'asthma' named entity 'prednisolone' named entity 'T-cell' named entity 'power analysis' named entity 'eotaxin' named entity 'placebo' named entity 'viruses' named entity 'genome' named entity 'wheezing' named entity 'rhinovirus' named entity 'interferon' named entity 'asthma' named entity 'study population' named entity 'coinfection' named entity 'wheezing' named entity 'asthma' named entity 'infection' named entity 'wheezing' named entity 'asthma' named entity 'asthma' named entity 'epithelial cells' named entity 'genome' named entity 'wheezing' named entity 'rhinovirus' named entity 'prednisolone' named entity 'placebo group' named entity 'wheezing' named entity 'rhinovirus' named entity 'rhinovirus' named entity 'SPSS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software